期刊文献+
共找到188篇文章
< 1 2 10 >
每页显示 20 50 100
Blood typing and transfusion therapy in a patient with A2 subtype acute myeloid leukemia M2:A case report
1
作者 Xiao-Chuan Kuang Shi-Hua Zhang +2 位作者 Yi-Jing Cen Jian-Bo Zhang Yu-Song Liu 《World Journal of Clinical Cases》 SCIE 2023年第16期3813-3821,共9页
BACKGROUND Acute myeloid leukemia(AML)is one of the most common types of leukemia in adults.However,AML is relatively rare in the population overall,accounting for only about 1 percent of all cancers.Treatment for AML... BACKGROUND Acute myeloid leukemia(AML)is one of the most common types of leukemia in adults.However,AML is relatively rare in the population overall,accounting for only about 1 percent of all cancers.Treatment for AML can be very effective for some patients,yet it leaves others with serious and even life-threatening side effects.Chemotherapy is still the primary treatment for most AML,but over time,leukemia cells become resistant to chemotherapy drugs.In addition,stem cell transplantation,targeted therapy,and immunotherapy are currently available.At the same time,with the progression of the disease,the patient may have corresponding complications,such as coagulation dysfunction,anemia,granulocytopenia,and repeated infection,so transfusion supportive therapy will be involved in the overall treatment regime.To date,few articles have reported on blood transfusion treatment options for patients with ABO subtypes AML-M2.Blood transfusion therapy is an important supportive treatment for AML-M2,and accurate determination of patients'blood type is one of the most important steps in the treatment process.In this study,we explored blood typing and supportive treatment strategies for a patient with A2 subtype AML-M2 to provide the basis for treatment for all patients.CASE SUMMARY In order to determine the blood type of the patient,serological and molecular biological methods were used for reference tests,and the genetic background was studied to determine the patient's final blood type and select the appropriate blood products for infusion treatment.According to the results obtained by serological and molecular biological methods,the blood type of the patient was A2 subtype;the genotype was A02/001;the irregular antibody screening was negative,and anti-A1 was found in the plasma.According to the overall treatment plan,active anti-infection,elevated cells,component blood transfusion support,and other rescue and supportive treatments were given,and the patient successfully passed the stage of myelosuppression after chemotherapy.Re-examination of bone marrow smears showed that AL was in complete remission of bone marrow signs,and minimal residual leukemia lesions suggested no cells with obvious abnormal immunophenotype(residual leukemia cells<10-4).CONCLUSION The infusion of patients with A2 subtype AML-M2 with A irradiated platelets and O washing red blood cells can meet the needs of clinical treatment. 展开更多
关键词 AbO blood-group system A2 subtypes blood grouping and crossmatching blood transfusion acute myeloid leukemia Atypical blood transfusion
下载PDF
Coexistence of diffuse large B-cell lymphoma,acute myeloid leukemia,and untreated lymphoplasmacytic lymphoma/waldenström macroglobulinemia in a same patient:A case report
2
作者 Liu-Bo Zhang Lu Zhang +8 位作者 Hong-Lei Xin Yan Wang Hong-Yu Bao Qing-Qi Meng Su-Yu Jiang Xue Han Wan-Ru Chen Jian-Ning Wang Xiao-Feng Shi 《World Journal of Clinical Cases》 SCIE 2023年第18期4295-4305,共11页
BACKGROUND The Coexistence of myeloid and lymphoid malignancies is rare.Myeloid leukemia occurs more frequently as a secondary event in patients receiving chemotherapy agents for lymphoid malignancies.Synchronous diag... BACKGROUND The Coexistence of myeloid and lymphoid malignancies is rare.Myeloid leukemia occurs more frequently as a secondary event in patients receiving chemotherapy agents for lymphoid malignancies.Synchronous diagnoses of diffuse large B-cell lymphoma(DLBCL),acute myeloid leukemia(AML),and untreated lymphoplasmacytic lymphoma/Waldenström macroglobulinemia(LPL/WM)in the same patient have not been reported.Here we report one such case.CASE SUMMARY An 89-year-old man had a chest wall mass histopathologically diagnosed as DLBCL.The bone marrow and peripheral blood contained two groups of cells.One group of cells fulfilled the criteria of AML,and the other revealed the features of small B lymphocytic proliferative disorder,which we considered LPL/WM.Multiple chromosomal or genetic changes were detected in bone marrow mononuclear cells,including ATM deletion,CCND1 amplification,mutations of MYD88(L265P)and TP53,WT1 overexpression,and fusion gene of BIRC2-ARAP1,as well as complex chromosomal abnormalities.The patient refused chemotherapy because of old age and died of pneumonia 1 mo after the final diagnosis.CONCLUSION The coexistence of DLBCL,AML,and untreated LPL/WM in the same patient is extremely rare,which probably results from multiple steps of genetic abnormalities.Asymptomatic LPL/WM might have occurred first,then myelodysplastic syndromerelated AML developed,and finally aggressive DLBCL arose.Therefore,medical staff should pay attention to this rare phenomenon to avoid misdiagnoses. 展开更多
关键词 Diffuse large b-cell lymphoma acute myeloid leukemia Small b lymphocyte proliferative disorder Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia COEXISTENCE Case report
下载PDF
B-cell lymphoma-2 inhibition and resistance in acute myeloid leukemia
3
作者 Lindsay Wilde Sabarina Ramanathan Margaret Kasner 《World Journal of Clinical Oncology》 CAS 2020年第8期528-540,共13页
Spurred by better understanding of disease biology,improvements in molecular diagnostics,and the development of targeted therapies,the treatment of acute myeloid leukemia(AML)has undergone significant evolution in rec... Spurred by better understanding of disease biology,improvements in molecular diagnostics,and the development of targeted therapies,the treatment of acute myeloid leukemia(AML)has undergone significant evolution in recent years.Arguably,the most exciting shift has come from the success of treatment with the B-cell lymphoma-2 inhibitor venetoclax.When given in combination with a hypomethylating agent or low dose cytarabine,venetoclax demonstrates high response rates,some of which are durable.In spite of this,relapses after venetoclax treatment are common,and much interest exists in elucidating the mechanisms of resistance to the drug.Alterations in leukemic stem cell metabolism have been identified as a possible escape route,and clinical trials focusing on targeting metabolism in AML are ongoing.This review article highlights current research regarding venetoclax treatment and resistance in AML with a focus on cellular metabolism. 展开更多
关键词 acute myeloid leukemia b-cell lymphoma-2 Venetoclax METAbOLISM Leukemic stem cell RESISTANCE
下载PDF
Acute myeloid leukemia with t(11;19)(q23;p13.1) in a patient with a gastrointestinal stromal tumor undergoing imatinib therapy:A case report
4
作者 Hong Jun Kim Sun Kyung Baek +3 位作者 Chi Hoon Maeng Si-Young Kim Tae Sung Park Jae Joon Han 《World Journal of Clinical Cases》 SCIE 2020年第7期1251-1256,共6页
BACKGROUND Acute myeloid leukemia(AML)harboring 11q23 translocations is classified as therapy-related AML in patients who have undergone prior treatment with cytotoxic agents.There have been only a few reports of AML ... BACKGROUND Acute myeloid leukemia(AML)harboring 11q23 translocations is classified as therapy-related AML in patients who have undergone prior treatment with cytotoxic agents.There have been only a few reports of AML that subsequently developed during imatinib mesylate(IM)treatment for gastrointestinal stromal tumors(GISTs).CASE SUMMARY A 63-year-old woman was diagnosed with a hepatic GIST recurrence in April 2012;she was administered IM 400 mg/d.In November 2015,she developed dyspnea with pancytopenia while IM treatment was continued for 42 mo.A chromosome study using a bone marrow sample showed a 46,XX karyotype with t(11;19)(q23;p13.1)in 22 of 26 analyzed metaphase cells.Fluorescence in situ hybridization using the locus-specific indicator(11q23)gene break-apart probe showed positive rearrangement in 82%of interphase cells.Reverse-transcription polymerase chain reactions subsequently confirmed the KMT2A/ELL transcript.She achieved complete response with incomplete neutrophil recovery with two decitabine treatment cycles.After the third cycle of decitabine,the disease relapsed,and she refused further treatment.She died of hemorrhagic stroke 5 mo after diagnosis.To the best of our knowledge,this is the first report of AML with KMT2A gene rearrangements in a patient with a GIST receiving IM treatment.CONCLUSION Physicians should consider the potential risks of developing hematologic malignancies,including therapy-related AML,in patients with GISTs receiving IM treatment. 展开更多
关键词 acute myeloid leukemia Gastrointestinal STROMAL tumor IMATINIb KMT2A MYELODYSPLASTIC syndrome Case report
下载PDF
Resveratrol-downregulated Phosphorylated Liver Kinase B1 Is Involved in Senescence of Acute Myeloid Leukemia Stem Cells 被引量:7
5
作者 彭丹月 宋慧 刘凌波 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2015年第4期485-489,共5页
Summary: Senescence is an important obstacle to cancer development. Engaging a senescent response may be an effective way to cure acute myeloid leukemia (AML). The aim of this study was to examine the effect of res... Summary: Senescence is an important obstacle to cancer development. Engaging a senescent response may be an effective way to cure acute myeloid leukemia (AML). The aim of this study was to examine the effect of resveratrol-downregulated phosphorylated liver kinase B1 (pLKB1) on the senescence of acute myeloid leukemia (AML) stem cells. The protein expressions of pLKB 1 and Sirtuin 1 (SIRT1), a regulator ofpLKB1, were measured in CD34+CD38-KGla cells treated with resveratrol (40 μmol/L) or not by Western blotting. Senescence-related factors were examined, including p21 mRNA tested by real-time PCR, cell morphology by senescence-associated β-galactosidase (SA-β-gal) staining, cell pro- liferation by MTT assay and cell cycle by flow cytometry. Besides, apoptosis was flow cytometrically determined. The results showed that pLKB1 was highly expressed in CD34+CD38- KGla cells, and resveratrol, which could downregulate pLKB1 through activation of SIRT1, induced senescence and apoptosis of CD34+CD38- KGla cells. It was concluded that resveratrol-downregulated pLKB1 is in- volved in the senescence of AML stem cells. 展开更多
关键词 phosphorylated liver kinase b1 (pLKb1) Sirtuin 1 (SIRT1) RESVERATROL acute myeloid leukemia (AML) leukemia stem cells (LSCs) cellular senescence
下载PDF
Disseminated Fusarium bloodstream infection in a child with acute myeloid leukemia:A case report 被引量:1
6
作者 Jun-Jie Ning Xue-Mei Li Sheng-Qiu Li 《World Journal of Clinical Cases》 SCIE 2021年第21期6049-6055,共7页
BACKGROUND Disseminated Fusarium is rare in healthy children.Children with hematological tumors may have secondary fungal infections,including Fusarium infections,which are due to tumor bone marrow infiltration or pro... BACKGROUND Disseminated Fusarium is rare in healthy children.Children with hematological tumors may have secondary fungal infections,including Fusarium infections,which are due to tumor bone marrow infiltration or prolonged bone marrow suppression after chemotherapy.Because of the lack of typical clinical manifestations and effective antifungal drugs,early diagnosis and treatment of the disease are difficult,and the prognosis is poor.CASE SUMMARY The patient in this case was a 13-year-old female child with rash and fever as the first symptoms.She had the characteristics of the four stages of skin that are typical of Fusarium infection.She was diagnosed with disseminated Fusarium infection through skin biopsy and blood culture and diagnosed with Fusarium solani infection based on the morphological characteristics of the blood culture.After treatment with liposome amphotericin B combined with voriconazole,the child recovered.CONCLUSION This case highlights that for children with secondary agranulocytosis after receiving chemotherapy for hematological malignancies,once typical abnormal skin damage is found,the possibility of Fusarium infection should be considered,and voriconazole alone or in combination with polyenes may be the most effective anti-Fusarium drugs.Amphotericin B,the traditional drug of disseminated Fusarium disease,has a high mortality rate,and it is not recommended to use it alone.Adequate neutrophil counts are essential for the treatment of disseminated Fusarium bloodstream infection. 展开更多
关键词 FUSARIUM Liposomal amphotericin b VORICONAZOLE acute myeloid leukemia AGRANULOCYTOSIS Case report
下载PDF
4-Hydroxy phenyl Retinamide Preferentially Targets FLT3 Mutated Acute Myeloid Leukemia via ROS Induction and NF-κB Inhibition
7
作者 Xin-ying ZHAO Ran-ran ZHANG +4 位作者 Qian YE Fei QIU Hao-yu XU Feng-gui WEI Hui ZHANG 《Current Medical Science》 SCIE CAS 2020年第5期810-816,共7页
FMS-like tyrosine kinase 3(FLT3)mutation is strongly associated with poor prognosis in acute myeloid leukemia(AML).Though many FLT3 inhibitors have been developed for clinical application with 34%-56%complete remissio... FMS-like tyrosine kinase 3(FLT3)mutation is strongly associated with poor prognosis in acute myeloid leukemia(AML).Though many FLT3 inhibitors have been developed for clinical application with 34%-56%complete remission rate,patients would develop resistance sooner or later after initial response to tyrosine kinase inhibitors(TKIs),such as gilteritinib.And increasing studies have shown that several resistance related mutations of FLT3 emerged during the AML progression.Thus,further investigation is warranted for these FLT3mu,AML patients to achieve a better treatment outcome.4-Hydroxyphenyl retinamide(4-HPR)has been investigated extensively in animal models and clinical trials as an anticancer/chemopreventive agent and is currently used for protection against cancer development/recurrence,with minimal side effects.In this study,we performed gene-set enrichment analysis and found that down-regulated genes induced by 4-HPR were associated with FLT3-ITD gene sets.CD34+ AML stem/progenitor cells separated from 32 AML samples were treated with 4-HPR.Correlation analysis showed that AML cells with FLT3-ITD genetic alteration were more sensitive to 4-HPR treatment than those without FLT3-ITD.Next,we treated 22 primary AML cells with 4-HPR and found that 4-HPR was more toxic to AML cells with FLT3-ITD.These results indicated that 4-HPR was preferentially cytotoxic to all FLT3-ITD AML cells irrespective of stem/progenitor cells or blast cells.4-HPR-induced reactive oxygen species(ROS)production and NF-kB inhibition might be the reason of 4-HPR selectivity on FLT3 mutated AML cells. 展开更多
关键词 4-Hydroxyphenyl retinamide acute myeloid leukemia FLT3 mutations ROS induction NF-κb inhibition
下载PDF
Regulation of NFκB/P65 by MDM2 in Pediatric Acute Lymphoblastic Leukemia
8
作者 胡群 周木想 +4 位作者 刘双又 张柳清 刘爱国 郭艺杰 宋宇 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2003年第1期68-70,共3页
MDM2 was transfected to acute lymphoblastic leukemia (ALL) line EU-4 cell which lacks P53 expression and expresses very low levels of MDM2. The results showed that MDM2 up-regulated P65 expression in mRNA level and pr... MDM2 was transfected to acute lymphoblastic leukemia (ALL) line EU-4 cell which lacks P53 expression and expresses very low levels of MDM2. The results showed that MDM2 up-regulated P65 expression in mRNA level and protein level. The effect of adriamycin (ADM) on MDM2-transfected EU-4 cell was detected by MTT assay. It was found that MDM2 transfection could increase drug resistance of EU-4 cells to ADM as compared with parent cells. Since the expression of E-selectin is P65 dependent, E-selectin promoter-CAT construct and P65 and MDM2 expression plasmids were co-transfected to EU-4 cells, revealing that MDM2 increased P65-mediated transactivation of E-selectin promoter. In the absence of P65, MDM2 had no effect on the transactivation of E-selectin. Moreover, MDM2 antisense couldn't change the transactivation of E-selectin. It was concluded that MDM2 could up-regulate transcriptionally P65 expression; MDM2 increased drug resistance of leukemia cells to ADM; MDM2 elevated NF-kappaB activity in a P53-independent manner. 展开更多
关键词 acute lymphoblastic leukemia MDM2 NF-Κb
下载PDF
Rhinocerebral mucormycosis caused by Rhizopus oryzae in a patient with acute myeloid leukemia: A case report
9
作者 Ya-Hui Feng Wen-Wen Guo +5 位作者 Ya-Ru Wang Wen-Xia Shi Chen Liu Dong-Mei Li Ying Qiu Dong-Mei Shi 《World Journal of Dermatology》 2020年第1期1-9,共9页
BACKGROUND Rhinocerebral mucormycosis(RCM)is a rare fatal fungal infection which is on the increase among immunocompromised hosts such as patients who have had hematological cancers,or have received immunosuppressive ... BACKGROUND Rhinocerebral mucormycosis(RCM)is a rare fatal fungal infection which is on the increase among immunocompromised hosts such as patients who have had hematological cancers,or have received immunosuppressive drugs,corticosteroids,or other T cell suppressing agents.CASE SUMMARY We report a case of RCM caused by Rhizopus oryzae,one of the most common opportunistic pathogens,in a patient suffering from a fourth relapse of acute myeloid leukemia.The patient developed RCM after he had received long-term antibiotic agents and corticosteroids.The pathogen was isolated three times from nasal secretions collected from the deep parts of the nasal cavity and was identified by morphology and internal transcribed spacer sequencing.Blood infection was excluded by droplet digital polymerase chain reaction and blood culture.The patient was empirically treated with caspofungin and voriconazole for several days while the lesions continued to progress.The patient was given amphotericin B in combination with caspofungin after RCM was suspected,and the lesions improved over the course of treatment,which lasted several days.However,the patient eventually died of the primary disease.CONCLUSION This case indicates that immunosuppressive drugs,including corticosteroids and antimetabolites in hematological tumor,do increase the risk of infections of this type.Early diagnosis,prompt and frequent surgical debridement,and treatment with amphotericin B without delay are all essential in combatting RCM. 展开更多
关键词 MUCORMYCOSIS Rhinocerebral mucormycosis Rhizopus oryzae acute myeloid leukemia Amphotericin b Droplet digital polymerase chain reaction Case report
下载PDF
节律分子BMAL2对急性髓系白血病细胞有氧糖酵解和细胞增殖的影响
10
作者 贾卫静 牟佼 崔文静 《中国实验血液学杂志》 CAS CSCD 北大核心 2024年第2期402-408,共7页
目的:了解类芳烃受体核转位蛋白2(BMAL2)在急性髓系白血病(AML)中的表达及与患者预后的关系,分析其对AML细胞有氧糖酵解和增殖的影响。方法:应用实时定量PCR法检测AML患者和正常对照组的骨髓单个核细胞中BMAL2的表达情况。利用美国国家... 目的:了解类芳烃受体核转位蛋白2(BMAL2)在急性髓系白血病(AML)中的表达及与患者预后的关系,分析其对AML细胞有氧糖酵解和增殖的影响。方法:应用实时定量PCR法检测AML患者和正常对照组的骨髓单个核细胞中BMAL2的表达情况。利用美国国家生物技术信息中心公共数据库分析BMAL2表达与AML患者预后的相关性。通过慢病毒系统敲低AML细胞系HL-60和Kasumi-1中BMAL2的表达,葡萄糖摄取实验、乳酸含量实验、CCK-8法、细胞集落形成实验检测其对细胞糖代谢、细胞增殖的影响。结果:BMAL2 mRNA在AML中的表达水平显著高于正常对照组(P<0.01)。BMAL2表达高的AML患者总生存时间较低表达患者明显缩短(P<0.05)。敲低AML细胞系HL-60和Kasumi-1中的BMAL2后,细胞葡萄糖摄取减少,乳酸生成减少。RT-PCR及Western blot检测结果显示,BMAL2通过增强HIF1A的表达来促进AML细胞有氧糖酵解,进而促进细胞增殖。结论:BMAL2高表达于AML中,通过HIF1A增强AML细胞有氧糖酵解从而促进细胞增殖。 展开更多
关键词 类芳烃受体核转位蛋白2 糖代谢 细胞增殖 急性髓系白血病
原文传递
BCL-2抑制剂联合用药治疗老年急性髓系白血病的临床研究
11
作者 袁晓婧 朱晨雨 王勇强 《系统医学》 2024年第7期1-4,共4页
目的探讨B淋巴细胞瘤-2(B-cell Lymphoma-2,BCL-2)抑制剂联合用药在治疗老年急性髓系白血病中的治疗效果,为老年急性髓系白血病的治疗提供实践依据。方法选取甘肃省酒钢医院肿瘤血液科于2020年1月—2023年10月收治的30例老年急性髓系白... 目的探讨B淋巴细胞瘤-2(B-cell Lymphoma-2,BCL-2)抑制剂联合用药在治疗老年急性髓系白血病中的治疗效果,为老年急性髓系白血病的治疗提供实践依据。方法选取甘肃省酒钢医院肿瘤血液科于2020年1月—2023年10月收治的30例老年急性髓系白血病患者作为研究对象,按照随机数表法分为对照组(15例)和干预组(15例)。干预组采用BCL-2抑制剂联合用药治疗,对照组采用常规治疗方法。比较两组治疗后的效果和不良反应发生率。结果治疗后,干预组的好转率(86.67%)显著高于对照组(46.67%),差异有统计学意义(χ^(2)=5.400,P<0.05)。治疗后,干预组的血液学指标显著优于对照组,差异有统计学意义(P<0.05);干预组的免疫学指标优于对照组,差异有统计学意义(P<0.05);干预组不良反应总发生率显著低于对照组,差异有统计学意义(P<0.05)。结论BCL-2抑制剂联合用药在治疗老年急性髓系白血病患者中,能有效改善患者的血液学指标和免疫学指标,促进疾病的好转,降低不良反应发生率。 展开更多
关键词 bCL-2抑制剂 老年急性髓系白血病 维奈克拉
下载PDF
Update on acute myeloid leukemia stem cells:New discoveries and therapeutic opportunities 被引量:3
12
作者 Maximilian Stahl Tae Kon Kim Amer M Zeidan 《World Journal of Stem Cells》 SCIE CAS 2016年第10期316-331,共16页
The existence of cancer stem cells has been wellestablished in acute myeloid leukemia. Initial proof of the existence of leukemia stem cells(LSCs) was accomplished by functional studies in xenograft models making use ... The existence of cancer stem cells has been wellestablished in acute myeloid leukemia. Initial proof of the existence of leukemia stem cells(LSCs) was accomplished by functional studies in xenograft models making use of the key features shared with normal hematopoietic stem cells(HSCs) such as the capacity of self-renewal and the ability to initiate and sustain growth of progenitors in vivo. Significant progress has also been made in identifying the phenotype and signaling pathways specific for LSCs. Therapeutically, a multitude of drugs targeting LSCs are in different phases of preclinical and clinical development. This review focuses on recent discoveries which have advanced our understanding of LSC biology and provided rational targets for development of novel therapeutic agents. One of the major challenges is how to target the selfrenewal pathways of LSCs without affecting normal HSCs significantly therefore providing an acceptable therapeutic window. Important issues pertinent to the successful design and conduct of clinical trials evaluating drugs targeting LSCs will be discussed as well. 展开更多
关键词 leukemia stem cells Cancer stem cells acute myeloid leukemia Stem cell niche XENOTRANSPLANTATION PLERIXAFOR NF-ba b C-X-C chemokine receptor type 4
下载PDF
Synchronous diagnosis and treatment of acute myeloid leukemia and chronic lymphocytic leukemia:Two case reports 被引量:2
13
作者 Rong-Rong Chen Li-Xia Zhu +9 位作者 Lu-Lu Wang Xue-Ying Li Jia-Nai Sun Mi-Xue Xie Jing-Jing Zhu De Zhou Jian-Hu Li Xin Huang Wan-Zhuo Xie Xiu-Jin Ye 《World Journal of Clinical Cases》 SCIE 2021年第30期9144-9150,共7页
BACKGROUND The concurrence of acute myeloid leukemia(AML)and chronic lymphocytic leukemia(CLL)is rare.Previous reports of such cases have focused mainly on clinical diagnosis and characteristics,so the mechanism remai... BACKGROUND The concurrence of acute myeloid leukemia(AML)and chronic lymphocytic leukemia(CLL)is rare.Previous reports of such cases have focused mainly on clinical diagnosis and characteristics,so the mechanism remains unclear,and therapy options have been poorly explored.CASE SUMMARY Here,we report two cases of synchronous AML and CLL.Flow cytometry revealed two distinct abnormal cell populations(myeloblasts and lymphoid cells)according to scatter characteristics.CD5-positive B cell lymphoma with myeloid leukemia invasion was observed on lymph node biopsy.Chemotherapy regimens indicated for both AML and CLL were used in our patients,and our patients achieved complete response after chemotherapy.Next-generation sequencing of 88 genes was performed.CONCLUSION We conclude that early mutation and dysregulation at the hematopoietic stem cell stage and the accumulation of multiple rearrangements may cause the concurrence of CLL and AML.The treatment of infection and combination therapy aimed at the CLL component are significant in the management of patients with concurrent CLL and AML. 展开更多
关键词 acute myeloid leukemia Chronic lymphocytic leukemia b-cell lymphoma-2 inhibitors THERAPY Ten-eleven translocation-2 Case report
下载PDF
Gene mutations in a patient with chronic myelomonocytic leukemia and changes upon progression to acute myeloid leukemia and during treatment 被引量:2
14
作者 Jiaming Li Sujiang Zhang 《Oncology and Translational Medicine》 2019年第1期30-32,共3页
Objective Chronic myelomonocytic leukemia(CMML) has been categorized as an uncommon hematological malignancy with overlapping features of myelodysplastic syndromes(MDS) and myeloproliferative neoplasms that have an in... Objective Chronic myelomonocytic leukemia(CMML) has been categorized as an uncommon hematological malignancy with overlapping features of myelodysplastic syndromes(MDS) and myeloproliferative neoplasms that have an inherent risk of progressing to acute myeloid leukemia(AML). Methods This study presents a case of confirmed CMML combined with M protein, in which the molecular changes upon progression to AML and under decitabine(DAC) plus bortezomib therapy were reported by tracking variant allele frequency(VAF) of mutations in a series of bone marrow samples. Results First, variable sensitivity of clones was observed during DAC treatment, and incomplete mutation clearance may be associated with low overall response rate and unsustained response. Secondly, DAC cannot prevent the new genetic alterations and accumulation of genetic progression on treatment, leading to acute transformation. Finally, autoimmunity was found to have acted as an important pathogenetic factor, increasing the additive mutations that further drive the clonal evolution in CMML. Conclusion Overall, changes in mutations and clonal architecture during CMML progression or treatment are predictive of an early evaluation of therapeutic strategies in CMML. 展开更多
关键词 chronic myelomonocytic leukemia acute myeloid leukemia mutation DECITAbINE bORTEZOMIb PLATELETS SETD2 LILRb4
下载PDF
NF-κB promotes the stem-like properties of leukemia cells by activation of LIN28B 被引量:1
15
作者 Jianbiao Zhou Jing-Yuan Chooi +5 位作者 Ying Qing Ching Jessie Yiying Quah Sabrina Hui-Min Toh Yvonne Ng Tuan Zea Tan Wee-Joo Chng 《World Journal of Stem Cells》 SCIE 2018年第4期34-42,共9页
AIM To examine whether nuclear factor kappa B(NF-κB) activity regulates LIN28 B expression and their roles in leukemia stem cell(LSC)-like properties. METHODS We used pharmacological inhibitor and cell viability assa... AIM To examine whether nuclear factor kappa B(NF-κB) activity regulates LIN28 B expression and their roles in leukemia stem cell(LSC)-like properties. METHODS We used pharmacological inhibitor and cell viability assays to examine the relation between NF-κB and LIN28 B. Western blot and q RT-PCR was employed to determine their protein and m RNA levels. Luciferase reporter was constructed and applied to explore the transcriptional regulation of LIN28 B. We manipulated LIN28 B level in acute myeloid leukemia(AML) cells and investigated LSC-like properties with colony forming and serial replating assays. RESULTS This study revealed the relationship between NF-κB and LIN28 B in AML cells through drug inhibition and overexpression experiments. Notably,inhibition of NF-κB by pharmacological inhibitors reduced LIN28 B expression and decreased cell proliferation. We demonstrated that NF-κB binds to the-819 to-811 region of LIN28 B promoter,and transcriptionally regulates LIN28 B expression. LIN28 B protein was significantly elevated in NFκB1 transfected cells compared to vector control. Importantly,ectopic expression of LIN28 B partially rescued the self-renewal capacity impaired by pharmacological inhibition of NF-κB activity. CONCLUSION These results uncover a regulatory signaling,NF-κB/LIN28 B,which plays a pivotal role in leukemia stem cell-like properties and it could serve as a promising intervening target for effective treatment of AML disease. 展开更多
关键词 Nuclear factor KAPPA b LIN28b leukemia STEM cell acute myeloid leukemia
下载PDF
Poly(ferulic acid)nanocarrier enhances chemotherapy sensitivity of acute myeloid leukemia by selectively targeting inflammatory macrophages
16
作者 Weijian Zhang Xianyu Deng +6 位作者 Liying Wang Jian Wang Xiuting Guo Lianggui Huang Xinyi Wang Jun Wu Linjia Jiang 《Chinese Chemical Letters》 SCIE CAS CSCD 2024年第9期289-295,共7页
Macrophages,as a subset of innate immune cells,play a pivotal role in the initiation,maintenance,and resolution of inflammatory responses during tissue damage repair,defense against infections,and tumor progression.Ho... Macrophages,as a subset of innate immune cells,play a pivotal role in the initiation,maintenance,and resolution of inflammatory responses during tissue damage repair,defense against infections,and tumor progression.However,the mechanisms by which macrophages regulate inflammation in acute myeloid leukemia(AML)and their involvement in the chemotherapeutic effect remain elusive.In this study,we have identified that AML cells stimulate macrophage expansion by activating the colony-stimulating factor 1 receptor(CSF1R)pathway.The expanded macrophages activate nuclear factor kappa-B(NFκB)to induce the expression of inflammatory factors,thereby maintaining leukemic cell quiescence and promoting cell survival following chemotherapy.Furthermore,we have successfully utilized a poly(ferulic acid)nanocarrier to selectively target macrophages for inhibiting the NFκB-mediated inflammation,ultimately enhancing chemotherapy efficacy against AML.Taken together,our findings highlight the crucial role of macrophage-induced inflammation in conferring chemoresistance to AML,and demonstrate the potential of a targeted nanocarrier specifically designed for inflammatory macrophages to improve the AML chemotherapeutic outcomes. 展开更多
关键词 acute myeloid leukemia CHEMORESISTANCE MACROPHAGE Inflammation NFΚb
原文传递
秦巴硒菇提取物FA-2-b-β对白血病细胞K562/ADR多药耐药性的逆转作用
17
作者 白宇 冯文雯 孙延庆 《甘肃农业大学学报》 CAS CSCD 2023年第2期32-41,共10页
【目的】探讨中药秦巴硒菇提取物FA-2-b-β对慢性髓系白血病耐药细胞K562/ADR耐药性的逆转作用。【方法】采用CCK-8法检测细胞抑制率,流式细胞术检测细胞凋亡率、周期及细胞内药物蓄积情况,rt-PCR和Western blot法检测耐药及凋亡相关基... 【目的】探讨中药秦巴硒菇提取物FA-2-b-β对慢性髓系白血病耐药细胞K562/ADR耐药性的逆转作用。【方法】采用CCK-8法检测细胞抑制率,流式细胞术检测细胞凋亡率、周期及细胞内药物蓄积情况,rt-PCR和Western blot法检测耐药及凋亡相关基因/蛋白表达,免疫荧光法观察K562/ADR细胞膜蛋白P-gp表达。【结果】不同浓度的FA-2-b-β对K562/ADR耐药细胞具有增殖抑制作用,其半数抑制浓度为(3.42±0.395)mg/mL,并可将K562细胞周期阻滞在G_(0)/G_(1)期,K562/ADR细胞阻滞于G_(2)/M期,且胞内荧光显示药物蓄积量增多。Western-blot及rt-PCR示FA-2-b-β能够明显下调耐药基因p65、MDR1的表达,上调基因p53、IκB-α、Bax的表达。【结论】秦巴硒菇提取物FA-2-b-β抑制K562/ADR细胞增殖并诱导其凋亡,其机制可能是通过调控NF-κB信号通路实现的。 展开更多
关键词 秦巴硒菇 FA-2-b 慢性髓系白血病 多药耐药性
下载PDF
血清CysC、β_(2)-MG与急性髓系白血病患者去甲基化治疗效果的关系
18
作者 张彩虹 宿瑞俊 +1 位作者 黄彬涛 王志玲 《中国实验血液学杂志》 CAS CSCD 北大核心 2024年第4期1005-1010,共6页
目的:分析血清胱抑素C(Cys C)、β_(2)-微球蛋白(β_(2)-MG)与急性髓系白血病(AML)患者去甲基化治疗效果的关系。方法:使用前瞻性队列研究方法,纳入2019年2月-2022年1月内蒙古医科大学附属医院收治的98例AML患者进行研究,全部患者均接... 目的:分析血清胱抑素C(Cys C)、β_(2)-微球蛋白(β_(2)-MG)与急性髓系白血病(AML)患者去甲基化治疗效果的关系。方法:使用前瞻性队列研究方法,纳入2019年2月-2022年1月内蒙古医科大学附属医院收治的98例AML患者进行研究,全部患者均接受地西他滨(DAC)+HAG方案治疗,以28 d为1个疗程,治疗3-4疗程。每个疗程结束时评估患者的治疗效果,达到完全缓解(CR)的患者进入巩固治疗,全部疗程结束未达到CR的患者视为治疗失败。治疗前检查项目包括血常规参数、血清Cys C、β_(2)-MG,并统计患者一般临床资料。根据统计结果,使用logistic回归分析血清Cys C、β_(2)-MG与AML患者去甲基化治疗效果的关系;绘制受试者工作特征(ROC)曲线,以曲线下面积(AUC)评估血清Cys C、β_(2)-MG对AML患者去甲基化治疗效果的预测效能。结果:入组98例AML患者,治疗期间5例被剔除,最终93例患者完成化疗疗程,其中23例初次诱导化疗(1-2疗程)达到CR,再诱导化疗(3-4疗程)后11例达到CR,治疗成功率为36.56%(34/93)。去甲基化治疗失败患者预后不良、预后中等占比高于治疗成功患者,血小板(PLT)、血红蛋白(Hb)水平低于治疗成功患者,血清Cys C、β_(2)-MG表达水平高于治疗成功患者,差异有统计学意义(P<0.05)。logistic回归分析显示,血清Cys C、β_(2)-MG高表达及预后不良是AML患者去甲基化治疗失败的独立危险因素(OR>1,P<0.05)。ROC曲线显示,血清Cys C、β_(2)-MG单独及联合预测AML患者去甲基化治疗效果的AUC值分别为0.788、0.785、0.834。结论:AML患者去甲基化治疗失败与血清Cys C、β_(2)-MG高表达有关,治疗前检测血清Cys C、β_(2)-MG能够预测AML患者去甲基化治疗失败风险。 展开更多
关键词 急性髓系白血病 去甲基化治疗 胱抑素C β_(2)-微球蛋白
原文传递
PIM1基因对急性髓系白血病U937细胞增殖、凋亡及JAK2/STAT3信号通路的影响
19
作者 高鑫 储李婧 颜宗海 《中国实验血液学杂志》 CAS CSCD 北大核心 2024年第3期663-669,共7页
目的:探讨PIM1基因对急性髓系白血病(AML)U937细胞增殖、凋亡的影响,以及对JAK2/STAT3通路的调控作用。方法:收集初诊成人AML患者和单纯缺铁性贫血患者的骨髓单个核细胞,荧光定量PCR检测PIM1 mRNA表达。将AML细胞系U937细胞分为:U937组(... 目的:探讨PIM1基因对急性髓系白血病(AML)U937细胞增殖、凋亡的影响,以及对JAK2/STAT3通路的调控作用。方法:收集初诊成人AML患者和单纯缺铁性贫血患者的骨髓单个核细胞,荧光定量PCR检测PIM1 mRNA表达。将AML细胞系U937细胞分为:U937组(U937细胞正常培养)、Si-PIM1组(U937细胞转染含PIM1 mRNA的低表达腺病毒载体)、Si-NC组(U937细胞转染不含PIM1 mRNA的低表达腺病毒载体)、CoA1组(U937细胞中加入浓度为20μmol/L的JAK2激活剂CoA1)、Si-PIM1+CoA1组(U937细胞转染含PIM1 mRNA低表达的腺病毒载体并加入浓度为20μmol/L的CoA1)。培养24 h。荧光定量PCR和蛋白印迹法检测U937细胞PIM1 mRNA和蛋白、JAK2/STAT3通路、细胞周期、凋亡相关蛋白表达;噻唑蓝法检测细胞增殖活性;流式细胞术检测细胞周期变化及凋亡率。结果:AML患者骨髓单个核细胞中PIM1 mRNA表达水平高于单纯缺铁性贫血患者(P<0.05)。与U937组相比,Si-PIM1组细胞PIM1 mRNA和蛋白、p-JAK2/JAK2、p-STAT3/STAT3、Cyclin D1、CDK2蛋白、细胞增殖活性、S期比例、G2/M期比例降低(均P<0.05),p27、Caspase-3蛋白、G0/G1期、凋亡率升高(均P<0.05),而CoA1组上述指标的变化情况与Si-PIM1组正好相反,CoA1可逆转Si-PIM1对U937细胞的作用效果。U937组、Si-PIM1+CoA1组、Si-NC组U937细胞上述指标差异无统计学意义(P>0.05)。结论:敲低PIM1基因表达可抑制U937细胞增殖、促进凋亡,缓解ALM进程,且上述作用可能与抑制JAK2/STAT3通路活化有关。 展开更多
关键词 丝/苏氨酸激酶家族成员1 急性髓系白血病U937细胞 增殖 凋亡 Janus酪氨酸激酶2/信号转导及转录激活因子3通路
原文传递
Heliangin acts as a covalent ligand of RPS2 that disrupts pre-rRNA metabolic processes in NPM1-mutated acute myeloid leukemia 被引量:2
20
作者 Yin Feng Yefan Han +5 位作者 Anni Hu Yi Qu Yili Hu Hao Wu Xinzhi Wang Li He 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2023年第2期598-617,共20页
Although NPM1 mutations are frequently found in acute myeloid leukemia patients,therapeutic strategies are scarce and unsuitable for those who cannot tolerate intensive chemotherapy.Here we demonstrated that heliangin... Although NPM1 mutations are frequently found in acute myeloid leukemia patients,therapeutic strategies are scarce and unsuitable for those who cannot tolerate intensive chemotherapy.Here we demonstrated that heliangin,a natural sesquiterpene lactone,exerts favorable therapeutic responses in NPM1 mutant acute myeloid leukemia cells,with no apparent toxicity to normal hematogenous cells,by inhibiting their proliferation,inducing apoptosis,causing cell cycle arrest,and promoting differentiation.In-depth studies on its mode of action using quantitative thiol reactivity platform screening and subsequent molecular biology validation showed that the ribosomal protein S2(RPS2)is the main target of heliangin in treating NPM1 mutant AML.Upon covalent binding to the C222 site of RPS2,the electrophilic moieties of heliangin disrupt pre-rRNA metabolic processes,leading to nucleolar stress,which in turn regulates the ribosomal proteins-MDM2-p53 pathway and stabilizes p53.Clinical data shows that the pre-rRNA metabolic pathway is dysregulated in acute myeloid leukemia patients with the NPM1 mutation,leading to a poor prognosis.We found that RPS2 plays a critical role in regulating this pathway and may be a novel treatment target.Our findings suggest a novel treatment strategy and lead compound for acute myeloid leukemia patients,especially those with NPM1 mutations. 展开更多
关键词 acute myeloid leukemia Heliangin NPM1-mutation Differentiation Pre-rRNA COVALENT RPS2 p53 stabilization
原文传递
上一页 1 2 10 下一页 到第
使用帮助 返回顶部